Search | Page 39 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Understanding Prognosis in MDS

    ... the marrow is trying to make the correct amount of all blood cells as evidenced by the high degree of cellular activity—red blood cells, ... prognosis may suggest a more risky therapy, such as a stem cell transplant , be tried. A better prognosis that indicates a longer ...

    Interview last updated 05/02/2012 - 4:36pm.

  2. Supportive Care

    ... cause your bone marrow to produce more blood cells. They may be helpful for some patients, but they do not replace ... a family member) is willing and able to donate matching stem cells to you ...

    Page last updated 08/29/2013 - 4:20pm.

  3. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... or partially matched UCB unit with >/= 2.5 x10^7 nucleated cells/kg of recipient weight at the time of cryopreservation. No current ... . Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months. Patients who are taking ...

    Clinical Trial last updated 06/06/2016 - 3:37pm.

  4. Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

    ... or partially matched UCB unit with >/= 2.5 x10^7 nucleated cells/kg of recipient weight at the time of cryopreservation. No current ... . Prior allogeneic or autologous hematopoietic stem cell transplant in the last 6 months. Patients who are taking ...

    Clinical Trial last updated 06/03/2016 - 2:54pm.

  5. Matthew J. Walter, MD

    ... Professor Department of Medicine Oncology Division, Stem Cell Biology Section, Department of Genetics ... of genes that are important for splicing together RNA in cells were found to be mutated in up to 57% of MDS patients. How these ...

    Grant Recipient last updated 08/18/2014 - 10:07am.

  6. Clinical Trials Report for February 2015

    ... Study Coordinator Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia For ... studied. hATG is made from horse blood and targets immune cells known as T-lymphocytes. Since T-lymphocytes are believed to be involved ...

    Page last updated 01/29/2015 - 10:10am.

  7. Amer Zeidan, M.D.

    ... the patient’s own immune system to attack the cancer cells. Dr. Zeidan and his colleagues designed and initiated an ongoing trial ... and decitabine ) and are not candidates for stem cell transplantation. Studies have found that cancer cells can block the ...

    Bio last updated 03/11/2016 - 1:41pm.

  8. PNH 101: Understanding Diagnosis and Treatment

    ... a bone marrow failure disease that causes red blood cells to break apart. Doctors call this process hemolysis . This occurs ... eculizumab , immunosuppressive drug therapy , stem cell transplantation, and supportive therapies like blood transfusions. ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  9. PNH 101: Understanding Diagnosis and Treatment

    ... a bone marrow failure disease that causes red blood cells to break apart. Doctors call this process hemolysis . This occurs ... eculizumab , immunosuppressive drug therapy, stem cell transplantation, and supportive therapies like blood transfusions. ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  10. Myelodysplastic syndromes: What do hospitalists need to know?

    ... a blood disorder characterized by ineffective production of cells leading to low blood counts and risk of development of acute myeloid ... decitabine (Dacogen®), intensive chemotherapy, and stem cell transplantation.  Patients tend to tolerate azacitidine and ...

    Research Review last updated 05/02/2016 - 9:21am.